Omega-3 drug reduces ischemic events among statin-treated patients

  • Bhatt DL & al.
  • J Am Coll Cardiol
  • 18 Mar 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An omega-3 drug reduces ischemic events among patients taking statins and who have well-controlled low-density lipoprotein cholesterol and existing cardiovascular (CV) risk factors.
  • Treating 1000 patients could prevent 159 events each year.
  • Results are from planned analysis of Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) of icosapent ethyl (IE; Vascepa), a derivative of the omega-3 fatty acid eicosapentaenoic acid.

Why this matters

  • This drug is already used to lower high triglycerides.

Study design

  • REDUCE-IT data for 8179 patients taking IE 4 g/day or placebo followed for a median 4.9 years.
  • Primary composite endpoint: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina.
  • Secondary composite endpoint: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
  • Funding: Amarin Pharma, which markets Vascepa.

Key results

  • Overall, IE was associated with fewer primary endpoint events vs placebo:
    • 61 vs 89 per 1000 patient years;
    • Rate ratio, 0.70 (95% CI, 0.62-0.78; P<.0001> 
  • Similar reductions for secondary endpoint events. 

Limitations

  • Exploratory (but prespecified) analysis, used 1 post hoc method of several applied.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit